Lisa Miller, PharmD, MA, MSCP
Articles by Lisa Miller, PharmD, MA, MSCP
Menopause Is Everyone’s Business: Final Reflections on VMS Treatment and Pharmacist Empowerment
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Pharmacists step up in menopause care by educating patients, personalizing treatment for hot flashes, and closing follow-up gaps with new FDA-approved options.
Navigating Coverage and Cost: What Pharmacists Need to Know About Access to Non-Hormonal VMS Therapies
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Learn how pharmacists secure access to new therapies with copay cards, BlinkRx pricing, and prior-authorization tips that cut delays.
The Proactive Pharmacist: Building Menopause Knowledge and Closing Care Gaps in the Community
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around The Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians.
Better Together: Real-World Examples of Pharmacist-Provider Collaboration in VMS Management
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.
The Pharmacist as a Menopause Ally: Expanding the Role Beyond the Prescription
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.
Listening First: How to Start, Guide, and Personalize Menopause Conversations with Patient
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.
From Trial Data to Real-World Practice: Safety, Monitoring, and Patient Selection for VMS Treatment
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.
From Trial to Practice: Key Findings from the SKYLIGHT and OASIS Studies
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Phase 3 SKYLIGHT and OASIS trials show rapid, week-one relief of menopausal hot flashes, with key safety findings and mixed sleep benefits.
Two New Tools for VMS: A Clinical and Pharmacological Comparison of NK Receptor Antagonists
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP New NK3 receptor blockers target hypothalamic “KNDy” neurons, easing menopause hot flashes without hormones and gaining top guideline support.
NK3 as a Drug Target: From Scientific Discovery to Guideline-Recognized Therapy
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP New NK3 receptor blockers target hypothalamic ‘KNDy’ neurons, offering
KNDy Neurons Explained: The Brain Science Behind Hot Flashes and New Treatment Targets
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP How pharmacists can spot menopause beyond hot flashes, update hormone therapy knowledge, and collaborate on dosing amid estrogen patch shortages.
Closing the Knowledge Gap: What Community Pharmacists Need to Know About Menopause
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Discover how community pharmacists can spot menopause beyond vasomotor symptoms, avoid HRT mix-up myths, and collaborate on safe, updated treatments.
Beyond Hot Flashes: How Our Understanding of Menopause and VMS Has Evolved
ByBrooke Griffin, PharmD, BCACP,Veronica P. Vernon, PharmD, MSCP, BCPS, BCACP, FAPhA,Stephanie Young Moss, PharmD, MHSA ,Lisa Miller, PharmD, MA, MSCP ,Lisa Chacko, MD, MPH, MSCP Learn how menopause VMS stem from the brain, last years, affect heart risk, and when hormone therapy is considered safe.
